Remission and active disease in rheumatoid arthritis: defining criteria for disease activity states.
about
Celecoxib for rheumatoid arthritisClinical outcome measures in juvenile idiopathic arthritisClinical trials of new drugs for the treatment of rheumatoid arthritis: focus on early disease2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritisOutcomes related to methotrexate dose and route of administration in patients with rheumatoid arthritis: a systematic literature reviewEffects of Achieving Target Measures in Rheumatoid Arthritis on Functional Status, Quality of Life, and Resource Utilization: Analysis of Clinical Practice Data.[Measuring disease activity for rheumatoid arthritis]Disease activity level, remission and response in established rheumatoid arthritis: performance of various criteria sets in an observational cohort, treated with anti-TNF agentsEvidence for predictive validity of remission on long-term outcome in rheumatoid arthritis: a systematic review.Secukinumab treatment in rheumatoid arthritis is associated with incremental benefit in the clinical outcomes and HRQoL improvements that exceed minimally important thresholds.Disease activity in psoriatic arthritis: comparison of the discriminative capacity and construct validity of six composite indices in a real world.HDL cholesterol efflux capacity in rheumatoid arthritis patients: contributing factors and relationship with subclinical atherosclerosis.Clinical Characteristics of Rheumatoid Arthritis Patients Achieving Functional Remission with Six Months of Biological DMARDs TreatmentEfficacy and safety of golimumab as add-on therapy to disease-modifying antirheumatic drugs: results of the GO-MORE study.Joint damage in rheumatoid arthritis progresses in remission according to the Disease Activity Score in 28 joints and is driven by residual swollen joints.Motivations for inadequate persistence with disease modifying anti-rheumatic drugs in early rheumatoid arthritis: the patient's perspective.Treating rheumatoid arthritis to target: recommendations of an international task force.2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis.Applying science in practice: the optimization of biological therapy in rheumatoid arthritis.Pooled indices to measure rheumatoid arthritis activity: a good reflection of the physician's mind?Clinical and functional remission: even though biologics are superior to conventional DMARDs overall success rates remain low--results from RABBIT, the German biologics register.American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials.Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate.Performance of the new 2011 ACR/EULAR remission criteria with tocilizumab using the phase IIIb study TAMARA as an example and their comparison with traditional remission criteria.Consensus statement on the use of rituximab in patients with rheumatoid arthritisVitamin D Is a Good Marker for Disease Activity of Rheumatoid Arthritis DiseaseHyperlipidemia in rheumatoid arthritis patients in Saudi Arabia. Correlation with C-reactive protein levels and disease activity.Attainment and characteristics of clinical remission according to the new ACR-EULAR criteria in abatacept-treated patients with early rheumatoid arthritis: new analyses from the Abatacept study to Gauge Remission and joint damage progression in methSex Differences in the Effects of a Biological Drug for Rheumatoid Arthritis on Depressive StateSerum levels of CXCL13 are associated with ultrasonographic synovitis and predict power Doppler persistence in early rheumatoid arthritis treated with non-biological disease-modifying anti-rheumatic drugs.Subclinical synovitis detected by macrophage PET, but not MRI, is related to short-term flare of clinical disease activity in early RA patients: an exploratory studyComparison of composite measures of disease activity in an early seropositive rheumatoid arthritis cohort.Factors that influence fatigue status in patients with severe rheumatoid arthritis (RA) and good disease outcome following 6 months of TNF inhibitor therapy: a comparative analysisRemission by composite scores in rheumatoid arthritis: are ankles and feet important?Interpreting the multi-biomarker disease activity score in the context of tocilizumab treatment for patients with rheumatoid arthritisCalprotectin and TNF trough serum levels identify power Doppler ultrasound synovitis in rheumatoid arthritis and psoriatic arthritis patients in remission or with low disease activity.Decreased PERP expression on peripheral blood mononuclear cells from patient with rheumatoid arthritis negatively correlates with disease activityAssociation Between Ischemic Stroke and Tumor Necrosis Factor Inhibitor Therapy in Patients With Rheumatoid Arthritis.Comorbidities are associated with poorer outcomes in community patients with rheumatoid arthritis.Defining remission in rheumatoid arthritis: results of an initial American College of Rheumatology/European League Against Rheumatism consensus conference
P2860
Q24186209-936FC487-5FF2-43FE-B3FB-DA5686AF555CQ26752701-292743BA-0612-4784-A4F4-0E15F1E48F8BQ26753120-ECFBCFCD-3B5B-4CA9-9C94-78253E97A1F5Q26828418-0B966643-5100-408D-8C66-37C912E32528Q26995202-CEE671FA-B9D6-46B3-9FDF-D3AA417CBE3BQ30984829-60BDD143-BE1D-4E44-B3F5-4EC33D78C0C8Q33234551-48EFCE38-D95A-487E-ACB7-F225EDDB82C8Q33434163-A237B868-37D2-4506-9BD2-641D3CDBD739Q33535269-FD02003A-3DE3-4AE9-A5C1-57BBF9BB9517Q33591510-5D5586C1-9CE7-4591-BAB1-A46F119D6233Q33747197-F11DAD5A-55EC-4189-A21F-DFE5825A797FQ33750044-89EB8B97-C6B5-4896-9293-22A6874EC9A3Q33781115-8E2345E3-A1E7-46FE-9098-03ADAF8201C4Q33956485-B5398A90-ED49-4EC4-8379-DC413B181035Q34033218-B6335105-4ADA-4F03-BFB0-DA366FBBB747Q34449612-C62A9FCC-E4E8-4E26-9199-859EAFDAC3E5Q34462557-BB66E0B8-44CA-4F69-A44B-B65923541E2CQ34500921-8DAC1350-8263-4A5A-BEE3-4314F5CD8F39Q34613898-C073586C-FF11-4B74-9FDF-603EF7E64A09Q34896529-75CDDB0D-85DC-4597-A2B6-6730FB74E6C8Q34897423-B9DCB760-2FE6-43A2-B38A-FC40BEDE6D9BQ35047250-3033BD02-442D-45BC-9674-59D3361A2B05Q35048395-FD0D962A-DE0A-4CC8-94A5-B9D0A9FB9157Q35249630-F9132518-2E40-4E82-AACE-57AB5CED1D89Q35638676-B499E0A0-E3EE-471C-B7D8-793C6232D114Q35639448-BFDB5D22-DC6A-492C-9C85-A5C81F4AF28AQ35681167-48D3FE50-97C4-44CF-A6C8-4E1452ED9F08Q35827953-C8994702-77BE-409C-AB24-BFFC86043F58Q35970365-0F655285-4302-4C5D-B108-5381C5AAF3A9Q36085027-5831959C-A3C3-46C2-AE40-5E4DEBA42D7FQ36092748-A3B8BBBF-0CEB-4F64-9A1E-F7D92B0FE323Q36171802-408A8359-A0E0-4BBA-8881-9C16FF5B4AD7Q36220823-5B99D4E7-BD29-44E1-BEBD-50B5F158203BQ36392370-90B48C89-3D7D-4F12-98CD-A6F3BC413996Q36492279-C0C8A976-433F-4963-9BF7-C4EF502FC6ABQ37080199-BC01D9EE-2FB3-4CED-9F75-745DC1A9BA87Q37162818-6D8A6781-E304-4A0F-AD2D-DA3C346D3EE5Q37169541-E6D564C4-3F7E-4995-833C-87FC8BE6446AQ37177578-BDA38356-6E27-40C2-9232-A1BED7F9955DQ37191449-32F91F73-E769-4072-91C7-9C08884B1BA5
P2860
Remission and active disease in rheumatoid arthritis: defining criteria for disease activity states.
description
2005 nî lūn-bûn
@nan
2005 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Remission and active disease i ...... a for disease activity states.
@ast
Remission and active disease i ...... a for disease activity states.
@en
type
label
Remission and active disease i ...... a for disease activity states.
@ast
Remission and active disease i ...... a for disease activity states.
@en
prefLabel
Remission and active disease i ...... a for disease activity states.
@ast
Remission and active disease i ...... a for disease activity states.
@en
P2093
P356
P1476
Remission and active disease i ...... a for disease activity states.
@en
P2093
Daniel Aletaha
Michael M Ward
Tanja Stamm
Valerie P K Nell
P304
P356
10.1002/ART.21235
P577
2005-09-01T00:00:00Z